NVST vs. ABT: Which Stock Should Value Investors Buy Now?

Zacks Investment Research suggests Envista (NVST) is a more attractive value investment than Abbott (ABT) based on its superior Zacks Rank (#2 Buy vs. #3 Hold) and more favorable valuation metrics. NVST exhibits a lower forward P/E ratio (18.49 vs. 25.87), PEG ratio (1.21 vs. 2.52), and P/B ratio (1.06 vs. 4.73) compared to ABT, resulting in a Value grade of B versus C, respectively.

Analysis

Envista (NVST) presents a more compelling value proposition compared to Abbott (ABT) within the Medical - Products sector, according to the provided analysis. NVST holds a Zacks Rank of #2 (Buy), indicative of a positive earnings estimate revision trend and an improving analyst outlook, contrasting with ABT's #3 (Hold) rank. This assessment is further substantiated by key valuation metrics: NVST's forward P/E ratio of 18.49 is considerably lower than ABT's 25.87. Similarly, NVST's PEG ratio of 1.21, which incorporates expected earnings growth, is more attractive than ABT's 2.52. Furthermore, NVST's price-to-book (P/B) ratio stands at 1.06, significantly below ABT's 4.73. These quantitative factors contribute to NVST earning a Value grade of B, superior to ABT's C grade, positioning NVST as the favored value investment between the two based on this specific comparative analysis.

Key Decisions for Investors

• Value-oriented investors should consider Envista (NVST) due to its #2 (Buy) Zacks Rank, more favorable valuation multiples (P/E 18.49, PEG 1.21, P/B 1.06), and superior Value Grade B compared to Abbott (ABT).
• The improving earnings estimate revision trend for NVST suggests a positive analyst outlook, which may warrant further investigation for potential capital appreciation.
• Investors holding or considering Abbott (ABT) for its value characteristics might re-evaluate its current valuation (P/E 25.87, PEG 2.52, P/B 4.73, Value Grade C) relative to peers like NVST, especially if a pure value strategy is paramount.